Immuno & Gene Therapy Committee

 Charter

 The Immuno & Gene Therapy Committee strives to:

  • Assist in the planning of the annual meeting scientific program and the review of submitted abstracts in the dendritic cell and immunotherapy category.
  • Review the status of the immuno & gene therapy field and compile a list of major scientific issues that must be addressed to advance or enable cellular therapies utilizing immunotherapy and gene therapy.
  • Publish position papers and engage in scientific discourse as necessary to advance the field.

 

Selected Publications

Emerging Trends in COVID-19 Treatment: Learning from Inflammatory Conditions Associated with Cellular Therapies (Cytotherapy. 2020 May; 000:1-8)

The Immuno-Gene Therapy Scientific Committee of the International Society for Cell & Gene Therapy (ISCT) sponsored a 2019 special edition in ISCT's flagship journal, Cytotherapy, with the goal of disseminating information about best-practice testing for a variety of cell types. 

Cytotherapy, March 2019, Volume 21, Issue 3

Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen specific T cells (Cytotherapy. 2019 Mar;21(3):278-288)

Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency (Cytotherapy. 2019 Mar;21(3):289-306)

Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process (Cytotherapy. 2019 Mar;21(3):307-314)

Characterization of human natural killer cells for therapeutic use (Cytotherapy. 2019 Mar;21(3):315-326)

Manufacturing chimeric antigen receptor T cells: issues and challenges (Cytotherapy. 2019 Mar;21(3):327-340)

T-cell receptor gene-modified cells: past promises, present methodologies and future challenges (Cytotherapy. 2019 Mar;21(3):341-357)

Chemistry, manufacturing and controls for gene modified hematopoietic stem cells (Cytotherapy. 2019 Mar;21(3):358-366)

Proposal for the International Society for Cell & Gene Therapy position statement on assays for the quality control and potency assessment of adoptive cellular immunotherapies (Cytotherapy. 2019 Mar;21(3):367-375)

 


Committee Members:



  
Patrick Hanley, PhD
Co-Chair (January 2018 - Present)
Children's National Health System
Washington, DC, United States
Sandeep Soni, MD
Co-Chair (May 2020 - Present)
CRISPR Therapeutics
San Francisco, CA, United States
  
Maria Ester Bernardo, MD, PhD
San Rafaele Scientific Institute
Rome, Italy
Alexey Bersenev, MD, PhD
Yale University
New Haven, CT, United States
   
Jaap Jan Boelens, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY, United States
Lisa Butterfield, PhD
Parker Institute for Cancer Immunotherapy
San Francisco, CA, United States
   
Mitchell Cairo, MD
New York Medical College
New York, NY, United States
Andrew Fesnak, MD
University of Pennsylvania
Philadelphia, PA, United States
   
David Gottlieb, MBBS, FRACP, FRCPA, MD
Westmead Hospital
Sydney, NSW, Australia
Michael Gustafson, PhD
Mayo Clinic Arizona
Phoenix, AZ, United States
   
Wei Dong Han, MD
Chinese PLA General Hospital
Beijing, China
Donald Kohn, MD
University of California Los Angeles (UCLA)
Los Angeles, CA, United States
   
Bruce Levine, PhD
University of Pennsylvania
Philadelphia, PA, United States
Sung-Yun Pai, MD
Boston Children's Hospital
Boston, MA, United States
   
Paula Rio, PhD

Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)

Madrid, Spain

Cameron Turtle, MBBS, PhD, FRACP, FRCPA
Fred Hutchinson Cancer Research Center
Seattle, WA, United States
  

 

© 2020 ISCT. All rights reserved. 
ISCT, INTERNATIONAL SOCIETY FOR CELLULAR THERAPY and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy